Aatmaj Healthcare Limited (AATMAJ) — Multibagger Analysis

AI research on 1 Expansion / Order-win announcement by Aatmaj Healthcare Limited since August 2026 — deal magnitude, revenue and EPS impact, execution risk, and the actual return since each announcement measured from the next trading day's open and benchmarked against the Nifty Smallcap 250.

Updates

03 August 2026 · Expansion · Possible · Healthcare · score 45/100

Deal

Deal value—

Deal vs businessAcquisition adds ₹9.0–9.5 Cr incremental revenue vs ₹44 Cr TTM revenue (~21% uplift)

Execution period1.0 yr

Fundamental gradeC

AI projections

Revenue uplift (yr1 / steady)21.0% / 21.0%

EPS uplift65.0%

Upside base / bull / bear35.0% / 75.0% / -30.0%

Horizon12-24 months

Realized market record

Entry — next-day open (04 Aug 2026)₹19.75

Latest close (15 Oct 2026)₹22.0

Return since+11.4%

α vs Smallcap 250+13.9%

α vs own sectorshown once held 90+ days — Healthcare median is -12.1% over 22 matured picks

Positives

Q1 FY27 revenue surge of 60% YoY to ₹8.13 Cr with pre-tax/depreciation margin improving from 11.1% to 18.8%.
Inorganic expansion via Anand Hospital acquisition adding ₹9-9.5 Cr top-line (21% increase over TTM revenue).
Bed capacity expansion from 130 to 330 beds, with potential trajectory to 430 beds.
Specialty addition with CTVS department at Jupiter Hospital and new IVF centre at Karelibaug.
Low valuation base at 0.8x P/B and ₹41 Cr market cap.

Risks

Depressed ROCE (3.6%) and volatile operating margins historically (OPM dropped from ~30% in FY23 to 8.9% TTM).
High working capital risk due to dependency on PMJAY government scheme reimbursement delays.
100% regional concentration in the Gujarat healthcare market.
Debt burden of ₹21 Cr against TTM PAT of ₹1 Cr (D/E of 0.41x).

Full AI brief

Aatmaj Health (AATMAJ) — Catalyst & Growth Potential Analysis

1. Catalyst Assessment & Ramp-Aware Impact Math

Announcement Summary: On 2026-08-03, Aatmaj reported Q1 FY27 revenue of ₹8.13 Cr (+60% YoY) and pre-tax/depreciation profit of ₹1.52 Cr (+170% YoY). The company announced the acquisition of Anand Hospital in Vadodara, expected to contribute ₹9.0–9.5 Cr in FY27 revenue.
Revenue Impact Math:
Baseline TTM Revenue = ₹44.0 Cr.
Incremental revenue from Anand Hospital = ~₹9.25 Cr (midpoint).
Steady-state annual revenue uplift = 9.25 / 44.0 = +21%.
Year 1 revenue expected to reach ~₹53.25 Cr.
Margin & EPS Impact Math:
Operating margin in Q1 FY27 reached 18.76% (pre-tax/depreciation). Assuming steady-state net margin of 5.5–6.5% on incremental hospital revenues, additional PAT = ₹0.55–0.60 Cr.
Baseline TTM PAT = ₹1.0 Cr (EPS ₹0.61).
Incremental PAT increases total net profit to ~₹1.60–1.65 Cr, representing a +65% EPS uplift.

2. Industry Context & Operational Feasibility

Industry: Healthcare & Hospital Operations.
Capital Intensity: HIGH (requires continuous outlay for hospital acquisitions, medical equipment, CTVS/IVF infrastructure).
Execution Difficulty: Moderate to High. Integrating acquired hospitals (Anand Hospital) and scaling occupancy requires operational management, clinical talent retention, and working capital buffer.
Expected Industry CAGR: 12%–15%.

3. Fundamental Quality & Financial Health

ROCE: 3.6% — current capital efficiency is very low due to unmonetized capex and recent hospital integrations.
Balance Sheet: Debt of ₹21 Cr on Net Worth of ₹51 Cr (D/E 0.41x). Partial recovery of 5% old debt provides marginal relief.
Promoter Holding: Stable at 64.33%.
Client & Payment Concentration Risk: High reliance on government PMJAY schemes leads to extended working capital cycles and settlement delays.

4. Valuation & Re-rating Potential

Current Price: ₹18.5 | Market Cap: ₹41 Cr | Trailing P/E: 30.3x | P/B: 0.8x.
Peer median trailing P/E is ~69.5x, reflecting small-cap valuation discount for Aatmaj due to execution track record and low ROCE.

5. Scenario Analysis & Price Targets

Base Case (+35% upside to ₹25.0): Anand Hospital contributes ₹9 Cr revenue in FY27. Annualized revenue reaches ₹52 Cr and PAT reaches ₹1.6 Cr. Forward P/E re-rates modestly to 25x.
Bull Case (+75% upside to ₹32.4): Bed capacity utilization ramps quickly to 430 beds, PMJAY receivables normalize, margins improve to 8% PAT margin (PAT ~₹2.2 Cr). Market re-rates stock to 30x forward P/E.
Bear Case (-30% downside to ₹13.0): Acquisition integration delays and PMJAY payment lock-ups strain liquidity, keeping ROCE sub-4% and compressing net profit back to <₹0.8 Cr.

6. Verdict Rationale

Verdict: POSSIBLE (Score: 45/100).
The acquisition of Anand Hospital and strong Q1 FY27 print provide genuine top-line expansion (~21% uplift). However, low historical ROCE (3.6%), volatile net margins, and working capital risks tied to PMJAY keep the verdict at POSSIBLE rather than a high-conviction candidate.

Analysis as of 2026-08-03 (price ₹18.50) · AI research, not investment advice.

FollowTelegram

Verdicts and projections on this page are produced by an AI model from Aatmaj Healthcare Limited's public exchange filings and are not investment advice. "Return since" is measured from the opening price of the next trading day after each announcement to the latest available close, so it reflects a price an investor could actually have paid. See all analysed companies on Multibagger AI.